These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 1380229)
1. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Coates JA; Cammack N; Jenkinson HJ; Jowett AJ; Jowett MI; Pearson BA; Penn CR; Rouse PL; Viner KC; Cameron JM Antimicrob Agents Chemother; 1992 Apr; 36(4):733-9. PubMed ID: 1380229 [TBL] [Abstract][Full Text] [Related]
2. The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. Gray NM; Marr CL; Penn CR; Cameron JM; Bethell RC Biochem Pharmacol; 1995 Sep; 50(7):1043-51. PubMed ID: 7575660 [TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Schinazi RF; McMillan A; Cannon D; Mathis R; Lloyd RM; Peck A; Sommadossi JP; St Clair M; Wilson J; Furman PA Antimicrob Agents Chemother; 1992 Nov; 36(11):2423-31. PubMed ID: 1283296 [TBL] [Abstract][Full Text] [Related]
4. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Tisdale M; Kemp SD; Parry NR; Larder BA Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907 [TBL] [Abstract][Full Text] [Related]
5. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Mathez D; Schinazi RF; Liotta DC; Leibowitch J Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908 [TBL] [Abstract][Full Text] [Related]
6. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908 [TBL] [Abstract][Full Text] [Related]
7. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Hart GJ; Orr DC; Penn CR; Figueiredo HT; Gray NM; Boehme RE; Cameron JM Antimicrob Agents Chemother; 1992 Aug; 36(8):1688-94. PubMed ID: 1384425 [TBL] [Abstract][Full Text] [Related]
8. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. Merrill DP; Moonis M; Chou TC; Hirsch MS J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296 [TBL] [Abstract][Full Text] [Related]
9. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Gu Z; Gao Q; Fang H; Salomon H; Parniak MA; Goldberg E; Cameron J; Wainberg MA Antimicrob Agents Chemother; 1994 Feb; 38(2):275-81. PubMed ID: 7514855 [TBL] [Abstract][Full Text] [Related]
10. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391 [TBL] [Abstract][Full Text] [Related]
12. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Coates JA; Cammack N; Jenkinson HJ; Mutton IM; Pearson BA; Storer R; Cameron JM; Penn CR Antimicrob Agents Chemother; 1992 Jan; 36(1):202-5. PubMed ID: 1590690 [TBL] [Abstract][Full Text] [Related]
13. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. Wainberg MA; Salomon H; Gu Z; Montaner JS; Cooley TP; McCaffrey R; Ruedy J; Hirst HM; Cammack N; Cameron J AIDS; 1995 Apr; 9(4):351-7. PubMed ID: 7540846 [TBL] [Abstract][Full Text] [Related]
14. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine. Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638 [TBL] [Abstract][Full Text] [Related]
15. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Boucher CA; Cammack N; Schipper P; Schuurman R; Rouse P; Wainberg MA; Cameron JM Antimicrob Agents Chemother; 1993 Oct; 37(10):2231-4. PubMed ID: 7504909 [TBL] [Abstract][Full Text] [Related]
16. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. Gu Z; Fletcher RS; Arts EJ; Wainberg MA; Parniak MA J Biol Chem; 1994 Nov; 269(45):28118-22. PubMed ID: 7525567 [TBL] [Abstract][Full Text] [Related]
17. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. Salomon H; Belmonte A; Nguyen K; Gu Z; Gelfand M; Wainberg MA J Clin Microbiol; 1994 Aug; 32(8):2000-2. PubMed ID: 7527427 [TBL] [Abstract][Full Text] [Related]